PE20110309A1 - Peptidos de senalizacion de la crkl - Google Patents
Peptidos de senalizacion de la crklInfo
- Publication number
- PE20110309A1 PE20110309A1 PE2010001154A PE2010001154A PE20110309A1 PE 20110309 A1 PE20110309 A1 PE 20110309A1 PE 2010001154 A PE2010001154 A PE 2010001154A PE 2010001154 A PE2010001154 A PE 2010001154A PE 20110309 A1 PE20110309 A1 PE 20110309A1
- Authority
- PE
- Peru
- Prior art keywords
- crkl
- seq
- refers
- amino acids
- length
- Prior art date
Links
- 102100029375 Crk-like protein Human genes 0.000 title abstract 3
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000011664 signaling Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- OVHQWOXKMOVDJP-UHFFFAOYSA-N melitin Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(OC=2C=C3C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)=C(C=4C=CC(O)=CC=4)O3)=O)=C(O)C=2)OC(C)C1O OVHQWOXKMOVDJP-UHFFFAOYSA-N 0.000 abstract 2
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108010026389 Gramicidin Proteins 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 108010002616 Interleukin-5 Proteins 0.000 abstract 1
- 108010077497 KLA peptide Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 102000002938 Thrombospondin Human genes 0.000 abstract 1
- 108060008245 Thrombospondin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004905 gramicidin Drugs 0.000 abstract 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 238000002864 sequence alignment Methods 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A UN PEPTIDO DE SENALIZACION DE TUMORES AISLADO QUE TIENE UNA LONGITUD DE 100 AMINOACIDOS Y SE FIJA BAJO CONDICIONES FISIOLOGICAS A CELULAS QUE EXPRESAN CRKL, EL CUAL COMPRENDE UNA UNIDAD DE FIJACION DE LA CRKL QUE TIENE UNA LONGITUD DE 6 A 20 AMINOACIDOS Y TIENE UN GRADO DE SIMILITUD A UN MEJOR ALINEAMIENTO DE SECUENCIA A UNA REGION DE DOMINIO PSI DE LA INTEGRINA B1 (SEQ ID NO:47) DE 25% A 60%. DONDE DICHO PEPTIDO ESTA ADHERIDO A UNA MOLECULA O A UN COMPLEJO MACROMOLECULAR TAL COMO i) UN AGENTE PRO-APOPTOSIS COMO GRAMICIDINA, MELITINA, (KLAKLAK)2 (SEQ ID NO: 48), ENTRE OTROS; ii) UN AGENTE ANTI-ANGIOGENICO COMO TROMBOSPONDINA, ANGIOTENSINA, INTERLEUCINA 12, ENTRE OTROS; iii) UNA CITOCINA COMO IL-1, IL-2, IL-5, ENTRE OTROS; iv) UN VIRUS COMO PAPOVAVIRUS, ADENOVIRUS, VIRUS DEL HERPES, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE CANCER DE PROSTATA, SARCOMA, LEUCEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7442308P | 2008-06-20 | 2008-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110309A1 true PE20110309A1 (es) | 2011-06-19 |
Family
ID=41434721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010001154A PE20110309A1 (es) | 2008-06-20 | 2009-06-19 | Peptidos de senalizacion de la crkl |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110189095A1 (es) |
| EP (1) | EP2303913A4 (es) |
| JP (1) | JP2011525491A (es) |
| CN (1) | CN102105487A (es) |
| BR (1) | BRPI0915718A2 (es) |
| CA (1) | CA2728763A1 (es) |
| CL (1) | CL2010001498A1 (es) |
| CO (1) | CO6331291A2 (es) |
| CR (1) | CR20110034A (es) |
| EC (1) | ECSP10010729A (es) |
| IL (1) | IL210053A0 (es) |
| MX (1) | MX2010014173A (es) |
| PE (1) | PE20110309A1 (es) |
| WO (1) | WO2009155556A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101870734B (zh) * | 2010-05-25 | 2012-06-20 | 北京大学 | 一种抑制新生血管生成的融合多肽及其编码基因与应用 |
| CU23950B1 (es) * | 2011-03-21 | 2013-10-29 | Ct De Ingeniería Genética Y Biotecnología | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
| EP3024846A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
| PE20160991A1 (es) * | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| US9683018B2 (en) * | 2013-07-25 | 2017-06-20 | Novartis Ag | Disulfide cyclic polypeptides for the treatment of heart failure |
| TW201536814A (zh) * | 2013-07-25 | 2015-10-01 | Novartis Ag | 用於治療心臟衰竭之合成環狀多肽 |
| CN104250287B (zh) | 2013-09-11 | 2017-03-22 | 中山大学附属肿瘤医院 | 肿瘤靶向多肽及应用 |
| US10130650B2 (en) | 2014-01-27 | 2018-11-20 | The Children's Hospital Of Philadelphia | Compositions and methods for treating autoimmune and inflammatory diseases |
| CN108303539B (zh) * | 2018-01-31 | 2020-08-11 | 刘双萍 | 一种乳腺癌细胞检测生物试剂及应用 |
| CN110025577B (zh) * | 2019-03-19 | 2021-09-07 | 广东药科大学 | 一种多肽药物口服靶向系统M27-39@FA-MCNs复合体及其制备方法和应用 |
| CN109908369B (zh) * | 2019-04-28 | 2022-02-11 | 复旦大学附属金山医院 | 一种新的环状RNA circCRKL在前列腺癌治疗中的应用 |
| WO2025186514A1 (en) * | 2024-03-07 | 2025-09-12 | University Of Helsinki | Cancer cell targeting peptide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5667981A (en) * | 1994-05-13 | 1997-09-16 | Childrens Hospital Of Los Angeles | Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein |
| US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US7671010B2 (en) * | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| EP1546714A4 (en) * | 2002-08-30 | 2007-12-05 | Univ Texas | COMPOSITIONS AND METHODS FOR USE IN THE APPLICATION TO PEPTIDES FOR THE DIAGNOSIS AND THERAPY OF CANCER IN HUMANS |
| JP2008520207A (ja) * | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| US20120017338A1 (en) * | 2008-01-15 | 2012-01-19 | Wei Wu | Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits |
-
2009
- 2009-06-19 WO PCT/US2009/048024 patent/WO2009155556A2/en not_active Ceased
- 2009-06-19 EP EP09767865.0A patent/EP2303913A4/en not_active Withdrawn
- 2009-06-19 CN CN2009801292540A patent/CN102105487A/zh active Pending
- 2009-06-19 CA CA2728763A patent/CA2728763A1/en not_active Abandoned
- 2009-06-19 PE PE2010001154A patent/PE20110309A1/es not_active Application Discontinuation
- 2009-06-19 US US13/000,231 patent/US20110189095A1/en not_active Abandoned
- 2009-06-19 BR BRPI0915718A patent/BRPI0915718A2/pt not_active IP Right Cessation
- 2009-06-19 MX MX2010014173A patent/MX2010014173A/es not_active Application Discontinuation
- 2009-06-19 JP JP2011514861A patent/JP2011525491A/ja not_active Withdrawn
-
2010
- 2010-12-16 IL IL210053A patent/IL210053A0/en unknown
- 2010-12-20 CL CL2010001498A patent/CL2010001498A1/es unknown
- 2010-12-20 CO CO10159776A patent/CO6331291A2/es not_active Application Discontinuation
- 2010-12-29 EC EC2010010729A patent/ECSP10010729A/es unknown
-
2011
- 2011-01-20 CR CR20110034A patent/CR20110034A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102105487A (zh) | 2011-06-22 |
| EP2303913A4 (en) | 2013-07-24 |
| CO6331291A2 (es) | 2011-10-20 |
| ECSP10010729A (es) | 2011-04-29 |
| CR20110034A (es) | 2011-06-24 |
| MX2010014173A (es) | 2011-06-20 |
| CA2728763A1 (en) | 2009-12-23 |
| WO2009155556A2 (en) | 2009-12-23 |
| WO2009155556A3 (en) | 2010-04-08 |
| JP2011525491A (ja) | 2011-09-22 |
| CL2010001498A1 (es) | 2011-05-20 |
| BRPI0915718A2 (pt) | 2017-06-20 |
| EP2303913A2 (en) | 2011-04-06 |
| IL210053A0 (en) | 2011-02-28 |
| US20110189095A1 (en) | 2011-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110309A1 (es) | Peptidos de senalizacion de la crkl | |
| ES2539812T3 (es) | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos | |
| CY1122178T1 (el) | Πολυπεπτιδια | |
| MX337417B (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores. | |
| PE20140382A1 (es) | Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas | |
| CL2011000086A1 (es) | Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b. | |
| CL2012000238A1 (es) | Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b. | |
| ES2528133T3 (es) | Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos | |
| ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| CR20120026A (es) | Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
| CO5700784A2 (es) | Polipeptidos de virus de papiloma humano y composiciones in- munogenas | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2016001405A1 (es) | A peptide mixture | |
| CO7160097A2 (es) | Variantes de oxm pegilada | |
| AR108277A2 (es) | Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas | |
| ATE391791T1 (de) | Membran penetrierende peptide und deren anwendungen | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| CL2011000979A1 (es) | Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| CL2009000727A1 (es) | Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras. | |
| ATE509949T1 (de) | Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |